Vismodegib (GDC-0449; trade name Erivedge) and sonidegib (LDE-225; trade name Odomzo), both SMO inhibitors, have been approved for oral treatment of patients with BCC or those with recurrent, locally advanced BCC who are not suitable candidates for surgery or radiotherapy. Here, SMO is linked to skin basal cell carcinoma.